Company intelligence / Profile preview
Topadur Pharma AG
Schlieren, Zurich, Switzerlandtopadur.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 1
01
Overview
Topadur’s lead candidate TOP-N53 has completed a successful Phase I trial with good tolerability and efficacy markers. A Phase IIa trial for digital ulcers in systemic sclerosis patients was expected to finish mid–2024. The compound has orphan drug designation for this indication, enabling accelerated market access. Preclinical data show strong efficacy for wound healing and other pipeline assets are advancing toward clinical development for additional high-value indications such as alopecia, diabetic retinopathy, colorectal cancer, glaucoma, lung fibrosis, and medical aesthetics.
- Therapeutic areas
- PulmonologyRheumatologyOphthalmologyEndocrinologyDermatologyOncology
- Modalities
- Small molecules (dual-action drugs targeting cGMP-enzyme regulation system)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Oshen Holdings SA (co-development/licensing of TOP-M119 for alopecia in Greater China)ongoing partnering discussions with global pharma companies especially around wound healing/orphan drug programs.
Beyond the preview
Go deeper on Topadur Pharma AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Topadur Pharma AG.